MBT-1316

N/A

Report date: 2025/03/19 16:06:42

Base Information

Drug NameMBT-1316
Drug Alias NameMBT-1316
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHBV DNA Polymerase inhibitors
TargetsHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Junke Huayuan Pharmaceutical Technology Co LtdBeijing Meibeita Drug Research Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Junke Huayuan Pharmaceutical Technology Co LtdBeijing Meibeita Drug Research Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, ChronicHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A